Drug
Obrixtamig clinical trials
Also written BI 764532.
- studies test it
- 9
- open now
- 6
- in phase 3
- 2
- first study started
- 2020
Keep track of what changes. Save the obrixtamig studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
9 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 2
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 1
Boehringer Ingelheim (8) · Technische Universität Dresden (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses obrixtamig is read from its arms, and is right about nine times in ten.
Testing it · 9
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyRecruitingPhase 3Boehringer IngelheimNCT07472517Written as obrixtamig
- A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine CancerRecruitingPhase 1Boehringer IngelheimNCT05963867Written as BI 764532
- DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard ChemotherapyRecruitingPhase 3Boehringer IngelheimNCT07544654Written as Obrixtamig
- A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3RecruitingPhase 1Boehringer IngelheimNCT05916313Written as BI 764532
- A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the LungNot yet recruitingPhase 2Technische Universität DresdenNCT07561645Written as Obrixtamig
- DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersRecruitingPhase 2Boehringer IngelheimNCT05882058Written as BI 764532, dose 1
- DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung CancerActive, not recruitingPhase 1Boehringer IngelheimNCT06077500Written as BI 764532
- A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingPhase 1Boehringer IngelheimNCT04429087Written as Obrixtamig - parenteral 1
- A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingPhase 1Boehringer IngelheimNCT05879978Written as Obrixtamig
Given in every arm · 4 — obrixtamig is usual care beside what is tested
- A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)RecruitingPhase 1/2Boehringer IngelheimNCT07843940Written as Obrixtamig
- DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine CancersNot yet recruitingPhase 1/2Boehringer IngelheimNCT07707895Written as Obrixtamig
- DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine CancersActive, not recruitingPhase 1Boehringer IngelheimNCT06132113Written as BI 764532
- DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent ChemotherapyActive, not recruitingPhase 1Boehringer IngelheimNCT05990738Written as BI 764532
Codes
What other systems call obrixtamig · ClinicalTrials.gg INT018522
- UNII (FDA) Y09G7LIC1AOBRIXTAMIGOne source FDA
- NCI Thesaurus C177765ObrixtamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y09G7LIC1A | OBRIXTAMIG | One source FDA |
| NCI Thesaurus | C177765 | Obrixtamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.